- 3-Deoxysappanchalcone Inhibits Cell Growth of Gefitinib-Resistant Lung Cancer Cells by Simultaneous Targeting of EGFR and MET Kinases
-
Lee JY, Lee SO, Kwak AW, Chae SB, Cho SS, Yoon G, Kim KT, Choi YH, Lee MH, Joo SH, Park JW, Shim JH
- KMID: 2544067
- Biomol Ther.
- 2023 Jul;31(4):446-455.
- doi: 10.4062/biomolther.2023.070
The mechanistic functions of 3-deoxysappanchalcone (3-DSC), a chalcone compound known to have many pharmacological effects on lung cancer, have not yet been elucidated. In this study, we identified the comprehensive... -
- CITED
-
- Close
- SHARE
-
- Close
- miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37
-
Kim MS, Kim SH, Yang SH, Kim MS
- KMID: 2528214
- Cancer Res Treat.
- 2022 Apr;54(2):445-457.
- doi: 10.4143/crt.2021.622
Purpose With the identification of epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) cells, EGFR–tyrosine kinase inhibitors (TKIs) are being used widely as the first-line of treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Characterization of intracellular Ca2+ mobilization in gefitinib-resistant oral squamous carcinoma cells HSC-3 and -4
-
Kim MS, Kim MS
- KMID: 2524299
- Int J Oral Biol.
- 2021 Dec;46(4):176-183.
- doi: 10.11620/IJOB.2021.46.4.176
Oral squamous cell carcinoma (OSCC) metastasis is characterized by distant metastasis and local recurrence. Combined chemotherapy with cisplatin and 5-fluorouracil is routinely used to treat patients with OSCC, and the... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects
-
Moon SJ, Kim Y, Jeon JY, Park SJ, Kwak YG, Kim MG
- KMID: 2525614
- Transl Clin Pharmacol.
- 2021 Sep;29(3):171-179.
- doi: 10.12793/tcp.2021.29.e17
Gefitinib is an anti-cancer drug used to treat non-small cell lung cancer. The objective of this study was to compare the pharmacokinetics and evaluate the bioequivalence of 2 orally administered... -
- CITED
-
- Close
- SHARE
-
- Close
- Synergistic Effect of Laminin and Epidermal Growth Factor on Biological and Morphological Properties of Co-Cultured Myoblasts and Fibroblasts
-
Mat Afandi MA, Maarof M, Chowdhury SR, Idrus RBH
- KMID: 2509428
- Tissue Eng Regen Med.
- 2020 Dec;17(6):835-845.
- doi: 10.1007/s13770-020-00283-3
BACKGROUND: One of the long-standing problems of myoblasts in vitro expansion is slow cell migration and this causes fibroblast population to exceed myoblasts. In this study, we investigated the synergistic... -
- CITED
-
- Close
- SHARE
-
- Close
- Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
-
Jeong I, Song J, Bae SY, Lee SK
- KMID: 2468811
- J Cancer Prev.
- 2019 Dec;24(4):217-223.
- doi: 10.15430/JCP.2019.24.4.217
BACKGROUND: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is a limited factor in the treatment of non-small-cell lung cancer (NSCLC) patients. Therefore, ongoing studies... -
- CITED
-
- Close
- SHARE
-
- Close
- The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
-
Choi JY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Jo SJ
- KMID: 2437610
- Cancer Res Treat.
- 2019 Jan;51(1):169-177.
- doi: 10.4143/crt.2017.491
PURPOSE: Despite the successful use of tyrosine kinase inhibitors (TKIs) in cancer patients, their effect on herpes zoster development has not been studied. The aim of this study was to... -
- CITED
-
- Close
- SHARE
-
- Close
- Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after treatment with gefitinib
-
Park S, Park S, Choi H, Park JY, Lim HS, Park MJ, Kim SY
- KMID: 2411526
- Korean J Intern Med.
- 2018 Jan;33(1):211-213.
- doi: 10.3904/kjim.2015.276
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment with Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, Decreases Serum Cholesterol in Patients with Lung Cancer
-
Kang YE, Kim JM, Joung KH, Kim HJ, Ku BJ
- KMID: 2368803
- Korean J Obes.
- 2016 Dec;25(4):233-239.
- doi: 10.7570/kjo.2016.25.4.233
BACKGROUND: Statins are used to treat hypercholesterolemia; however, major cardiovascular events are decreased only 30% by statin treatment. Treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor has... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for patient with leptomeningeal metastasis of epidermal growth factor receptor mutant non-small cell lung cancer
-
Lee JS, Lee KA, Lee KH, Moon SY, Kim IA, Jeon SJ, Min JK, Kim HJ, Lee KY
- KMID: 2328118
- Yeungnam Univ J Med.
- 2016 Jun;33(1):64-67.
- doi: 10.12701/yujm.2016.33.1.64
We report on a 64-year-old man with leptomeningeal metastasis (LM) from an epidermal growth factor receptor (EGFR)-mutated adenocarcinoma of the lung. He was treated with paclitaxel, cisplatin. After completion of... -
- CITED
-
- Close
- SHARE
-
- Close
- Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
-
Kang JH, Ahn MJ, Kim DW, Cho EK, Kim JH, Shin SW, Wang X, Kim JS, Orlando M, Park K
- KMID: 2454321
- Cancer Res Treat.
- 2016 Apr;48(2):458-464.
- doi: 10.4143/crt.2015.135
PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
-
Beom SH, Kim DW, Sim SH, Keam B, Park JH, Lee JO, Kim TM, Lee SH, Heo DS
- KMID: 2152264
- Cancer Res Treat.
- 2016 Jan;48(1):88-97.
- doi: 10.4143/crt.2014.201
PURPOSE: Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated... -
- CITED
-
- Close
- SHARE
-
- Close
- Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
-
Kim YS, Cho EK, Woo HS, Hong J, Ahn HK, Park I, Sym SJ, Kyung SY, Kang SM, Park JW, Jeong SH, Park J, Lee JH, Shin DB
- KMID: 2152263
- Cancer Res Treat.
- 2016 Jan;48(1):80-87.
- doi: 10.4143/crt.2014.307
PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. MATERIALS AND METHODS: Patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
-
Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS
- KMID: 2381594
- Korean J Intern Med.
- 2015 Nov;30(6):891-898.
- doi: 10.3904/kjim.2015.30.6.891
BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. METHODS: Forty-five patients with NSCLC who were... -
- CITED
-
- Close
- SHARE
-
- Close
- The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib
-
Park DI, Kim SY, Kim JO, Jung SS, Park HS, Moon JY, Chung CU, Kim SS, Seo JH, Lee JE
- KMID: 2320699
- Tuberc Respir Dis.
- 2015 Oct;78(4):315-320.
- doi: 10.4046/trd.2015.78.4.315
BACKGROUND: The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in... -
- CITED
-
- Close
- SHARE
-
- Close
- Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis
-
Jeong CH
- KMID: 2171318
- J Cancer Prev.
- 2015 Mar;20(1):57-63.
- doi: 10.15430/JCP.2015.20.1.57
BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to non-small cell lung cancer (NSCLC) patients has been limited due to emergence... -
- CITED
-
- Close
- SHARE
-
- Close
- Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
-
Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH
- KMID: 2155291
- Clin Mol Hepatol.
- 2015 Mar;21(1):49-59.
- doi: 10.3350/cmh.2015.21.1.49
BACKGROUND/AIMS: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin... -
- CITED
-
- Close
- SHARE
-
- Close
- Gefitinib Inhibits the Growth of Toxoplasma gondii in HeLa Cells
-
Yang Z, Ahn HJ, Nam HW
- KMID: 1792207
- Korean J Parasitol.
- 2014 Aug;52(4):439-441.
- doi: 10.3347/kjp.2014.52.4.439
Toxoplasma gondii is the causative agent of toxoplasmosis with symptoms of congenital neurological and ocular diseases and acquired lymphadenitis, retinochoroiditis, and meningoencephalitis. Small molecules which block the activity of protein... -
- CITED
-
- Close
- SHARE
-
- Close
- Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases
-
Ryu YJ, Chun EM, Lee SN, Shim SS
- KMID: 1705587
- Korean J Radiol.
- 2014 Apr;15(2):300-304.
- doi: 10.3348/kjr.2014.15.2.300
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is... -
- CITED
-
- Close
- SHARE
-
- Close
- Radiation Recall Dermatitis Induced by Gefitinib
-
Kang B, Leem AY, Kim YJ, Hwang E, Yun Y, Kim SW, Kim HS
- KMID: 1726729
- Ewha Med J.
- 2013 Dec;36(Suppl):S17-S21.
- doi: 10.12771/emj.2013.36.S.S17
Radiation recall dermatitis refers to an acute inflammatory reaction in a previously irradiated field triggered by the administration of certain drugs days to years after the exposure to radiation. Gefitinib... -
- CITED
-
- Close
- SHARE
-
- Close
